Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-01

Study Completion Date

2021-06-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in hospitalized subjects with COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

NCT01598168

Heparin-induced Thrombocytopenia

TERMINATED PHASE3

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

NCT02846532

Thrombosis

COMPLETED PHASE3

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

NCT02564718

Thromboembolism

COMPLETED PHASE1/PHASE2

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

NCT01561924

Congenital Bleeding Disorder Haemophilia A With Inhibitors Haemophilia B With Inhibitors

COMPLETED PHASE1

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

NCT05042440

Hemophilia A

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As clinicians learn how to better care for hospitalized COVID-19 patients, the clinical picture of a hypercoagulable state with abnormal blood clotting has emerged. Fulminant heart, lung, kidney, and liver failure are hallmarks of COVID-19 non-survivors and have been associated with abnormal blood coagulation parameters, such as elevated D-Dimer levels. The current standard of care using prophylactic levels of subcutaneous heparin has not significantly mitigated the risk of patients entering a hypercoagulable state, however the dysregulated thrombotic and inflammatory events that drive poor outcomes in many COVID-19 patients may be amenable to early treatment with a factor Xa (FXa) inhibitor. The purpose of this study is to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous LMWH (Lovenox) in hospitalized subjects with COVID-19.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Open-label Multicenter Prospective Randomized Trial in hospitalized patients with severe acute respiratory syndrome (SARS)-CoV-2 infection. Patients will be randomized 1:1 to subcutaneous enoxaparin (Lovenox) versus rivaroxaban after hospitalization, with the exact dosing is based on an adaptive strategy.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Open label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adaptive Dosing: Enoxaparin

* Low 40mg subcutaneous (SQ) daily, or
* Intermediate 40mg SQ q12 hours, or
* Therapeutic 1mg/kg SQ q12 hours

Group Type ACTIVE_COMPARATOR

Enoxaparin

Intervention Type DRUG

Subcutaneous enoxaparin While hospitalized only.

Adaptive Dosing: Rivaroxaban

* Low 10mg po daily
* Intermediate 10mg po daily
* Therapeutic 20mg po daily

Group Type ACTIVE_COMPARATOR

Rivaroxaban

Intervention Type DRUG

Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enoxaparin

Subcutaneous enoxaparin While hospitalized only.

Intervention Type DRUG

Rivaroxaban

Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients age 18-100 admitted to hospital with laboratory-confirmed SARS-CoV-2 infection
* Not be intubated or mechanically ventilated or imminently at risk for same or ICU admission within 24 hours of enrollment.
* Not be admitted for central nervous system (CNS) diagnosis
* Not have a current history of a condition requiring full therapeutic anticoagulation such as venous thromboembolism, atrial fibrillation.

Exclusion Criteria

Medical Conditions

* Life expectancy of less than 6 months
* Active or recent gastrointestinal bleeding in the past 6 months
* Intracranial bleeding in the past 6 months
* Major trauma or head trauma in the past 2 months
* Major surgery in the past 2 months or planned within 2 weeks after completion of the study
* Recent spinal or epidural procedures in the past 2 weeks
* Ischemic stroke in the past 2 weeks
* History of intracranial neoplasm, arteriovenous malformation or aneurysm
* History of acquired or spontaneous impairment of hemostasis such as but not limited to hemophilia, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), von Willebrand disease
* Allergy to heparin or rivaroxaban or any factor Xa inhibitors, including a history of heparin-induced thrombocytopenia
* History of antiphospholipid syndrome
* End-stage renal failure requiring dialysis
* Valvular heart disease requiring chronic anticoagulation
* History of atrial fibrillation, atrial flutter or venous thromboembolic event (VTE) currently requiring anticoagulation
* History of solid organ transplant requiring immunosuppressant therapy
* Cancer requiring ongoing anticoagulation
* History of cirrhosis or liver failure, hepatorenal syndrome
* History of baseline bronchiectasis
* History of systemic lupus erythematosus or other autoimmune diseases requiring immunosuppressant therapy.

Vital signs

* Uncontrolled hypertension: systolic blood pressure (SBP) \> 180 mm Hg or diastolic blood pressure (DBP) \> 105mm Hg. Subjects who have a transient, higher blood pressure elevation (SBP 180-200 mm Hg) may enter the study if a repeat confirmation is back in range prior to enrollment.

Laboratory

* PT INR \> 2.0.
* Platelet \< 90 10\^3/µL
* Total bilirubin \> 3.0 mg/dL
* Hemoglobin \< 9.0 g/dL
* Urine with gross hematuria (not due to menses)
* Estimated glomerular filtration rate (GFR) less than 30 mL/min calculated with the Cockcroft-Gault formula

Medications

* Patients on dual anti-platelet therapy
* Patients taking hypoxia-inducible factor prolyl hydroxylase inhibitors (such as roxadustat.)
* Erythropoiesis-stimulating agents (such as epoetin alfa, darbepoetin alfa)

Other COVID-19 drug studies or trials

* Any COVID19 vaccination trials
* Experimental COVID drug trial except for treatment(s) that has become accepted standard of care.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No